

Nanotechnology and the Developing World

Peter A. Singer

McLaughlin-Rotman Centre for Global Health
Program in the Life Sciences, Ethics, and Policy
University Health Network and
University of Toronto


Greatest ethical challenge of our time





United Nations Millennium Development Goals



- **Eradicate extreme poverty and hunger**
- **Achieve universal primary education**
- **Promote gender equality and empower women**
- **Reduce child mortality**
- **Improve maternal health**
- **Combat HIV / AIDS, malaria, and other diseases**
- **Ensure environmental sustainability**
- **Develop a global partnership for development**



The Millennium Development Goals cannot be achieved without a focused policy for science, technology and innovation

**Which
nanotechnologies
are most likely to
benefit people in
developing
countries?**

63 panelists in 26 countries



13



50

Top 10 nanotechnologies for the developing world






1. Energy storage, production and conversion
2. Agricultural productivity enhancement
3. Water treatment and remediation
4. Disease diagnosis and screening
5. Drug delivery systems
6. Food processing and storage
7. Air pollution remediation
8. Construction
9. Health monitoring
10. Vector and pest detection and control

PLoS Med 2006; 2(5): e97


UHN | MCMM at University of Toronto

Top 10 nanotechnologies vs. Millennium Development Goals








Quantum dots



Dendrimers




Lab on a chip



Buckyballs

Quantum dots for malaria



Decreasing infrastructure requirement of malaria diagnostic tests saves most lives

Test	Sensitivity (%) [*]	Specificity (%) [*]	Adjusted lives saved SD [†]	Malaria-related deaths averted SD [‡]	Unnecessary treatments averted SD [§]	Total possible adjusted lives saved (%)
Moderate infrastructure [¶]						
1	95	95	635,993 (177,657)	15,396 (16,680)	141,845,100 (13,780,159)	23
2	100	100	720,178 (164,731)	61,453 (19,528)	153,500,465 (9,157,093)	26
Minimal infrastructure [¶]						
3	80	80	1,125,343 (398,332)	-260,221 (71,761)	302,893,523 (23,761,961)	40
4	90	80	1,329,135 (454,830)	-14,694 (38,983)	302,893,523 (26,929,491)	48
5	90	90	1,574,136 (199,153)	-14,694 (44,426)	365,028,106 (30,421,389)	57
6	90	95	1,696,636 (267,343)	-14,694 (39,784)	396,095,397 (30,041,704)	61
7	95	80	1,431,031 (402,001)	108,070 (61,464)	302,893,523 (32,129,807)	51
8	95	90	1,676,032 (480,430)	108,070 (48,312)	365,028,106 (31,842,147)	60
9 [*]	95	95	1,798,532 (557,684)	108,070 (54,660)	396,095,397 (19,853,132)	65
10	98	95	1,859,670 (393,620)	181,728 (45,921)	396,095,397 (39,734,068)	67
11	100	100	2,022,928 (288,721)	230,833 (53,055)	427,162,689 (29,167,835)	73
No infrastructure [¶]						
12	80	80	1,599,205 (429,882)	-6,596 (70,174)	364,781,060 (26,578,084)	57
13	90	80	1,868,415 (343,583)	317,746 (83,601)	364,781,060 (17,713,071)	67
14	90	90	2,192,062 (521,002)	317,746 (96,233)	446,861,090 (35,354,040)	79
15	90	95	2,353,885 (333,462)	317,746 (67,914)	487,901,105 (29,070,712)	85
16	95	80	2,003,021 (493,457)	479,917 (100,575)	364,781,060 (15,211,801)	72
17	95	90	2,326,667 (421,037)	479,917 (106,694)	446,861,090 (30,136,053)	84
18	95	95	2,488,490 (627,778)	479,917 (97,482)	487,901,105 (36,711,469)	89
19	98	95	2,569,253 (584,295)	577,220 (58,806)	487,901,105 (41,085,524)	92
20	100	100	2,784,919 (432,004)	642,088 (96,921)	528,941,121 (18,279,201)	100

Domestic innovation needed in developing world



Healthcare Biotechnology Innovation
in Developing Countries

nature
biotechnology
nature publishing group

- ✓ Strong and sustained political will
- ✓ Individual leadership
- ✓ Close linkages, active knowledge flow
- ✓ Focused efforts in niche areas
- ✓ Temporarily permissive IP environment for initial capacity building
- ✓ Private sector development

Examples of nanotechnology innovation in the developing world

- Nanodiagnostic systems for HIV, H-B, syphilis, pregnancy (Nano Biotech Ltd.)
- Nano drug delivery systems for cancer and for local delivery to eye and skin (CISR, U. Delhi, Dabur Research Foundation, Panacea Biotech)

MEXICO

Polymer nanocomposites for controlled drug release, nanoscaffolds, and dental materials

- Nanomagnets as drug transporters
- Carbon nanotubes for implants, prostheses, and biosensors

BRASIL

ARGENTINA

CHILE

SOUTH AFRICA



● Front runners

● Middle ground

● Up-and-comers



**Dr. Fabio
Salamanca-
Buentello**



BILL & MELINDA
GATES foundation



MERCK

IDRC



CRDI



GlaxoSmithKline



UHN | MCMM at University of Toronto

Additional funding partners listed at www.geneticethics.net